[go: up one dir, main page]

MX2009011076A - Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo. - Google Patents

Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo.

Info

Publication number
MX2009011076A
MX2009011076A MX2009011076A MX2009011076A MX2009011076A MX 2009011076 A MX2009011076 A MX 2009011076A MX 2009011076 A MX2009011076 A MX 2009011076A MX 2009011076 A MX2009011076 A MX 2009011076A MX 2009011076 A MX2009011076 A MX 2009011076A
Authority
MX
Mexico
Prior art keywords
group
therapeutic agent
cycloalkyl
glaucoma
hydrogen atom
Prior art date
Application number
MX2009011076A
Other languages
English (en)
Inventor
Jayson M Rieger
Robert D Thompson
Atsushi Shimazaki
Noriko Kawabata
Tomoko Kirihara
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2009011076A publication Critical patent/MX2009011076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se pretende investigar un agente terapéutico para glaucoma. Un compuesto representado por la siguiente fórmula general (1) o una sal del mismo muestra un excelente efecto de disminución de presión intraocular en una prueba para reducción de presión intraocular y es útil como un agente preventivo o terapéutico para glaucoma o hipertensión ocular (ver fórmula 1) en la fórmula, X representa CH o N; R1 representa un átomo de hidrógeno, un grupo hidroxi, un átomo de halógeno, un grupo alquilo, un grupo alcoxi, un grupo cicloalquilo, un grupo cicloalcoxi, un grupo (cicloalquil)metoxi o (ver fórmula) R2 representa un átomo de hidrógeno, un grupo alquilo, un grupo cicloalquilo, un grupo alquilcarbonilo o un grupo alquiloxicarbonilo; Ra y Rb son iguales o diferentes y representan un átomo de hidrógeno, un grupo hidroxi, un átomo de halógeno, un grupo alquilo, un grupo alcoxi, un grupo cicloalquilo o un grupo cicloalcoxi.
MX2009011076A 2007-04-16 2008-04-14 Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo. MX2009011076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007106915A JP2008266143A (ja) 2007-04-16 2007-04-16 アデノシン誘導体を有効成分として含有する緑内障治療剤
PCT/US2008/004770 WO2008130520A1 (en) 2007-04-16 2008-04-14 Therapeutic agent for glaucoma containing adenosine derivative as active ingredient

Publications (1)

Publication Number Publication Date
MX2009011076A true MX2009011076A (es) 2010-01-20

Family

ID=39875791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011076A MX2009011076A (es) 2007-04-16 2008-04-14 Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo.

Country Status (15)

Country Link
US (2) US20100093770A1 (es)
EP (1) EP2134174A4 (es)
JP (2) JP2008266143A (es)
KR (1) KR20090128495A (es)
CN (1) CN101677544A (es)
AU (1) AU2008241496A1 (es)
BR (1) BRPI0809953A2 (es)
CA (1) CA2684866A1 (es)
EA (1) EA015971B1 (es)
IL (1) IL201418A0 (es)
MX (1) MX2009011076A (es)
NZ (1) NZ580165A (es)
UA (1) UA100376C2 (es)
WO (1) WO2008130520A1 (es)
ZA (1) ZA200906989B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors
ME02608B (me) 2010-01-11 2017-06-20 Inotek Pharmaceuticals Corp Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
CN102822188A (zh) * 2010-03-26 2012-12-12 伊诺泰克制药公司 腺苷化合物及其用途
PH12012501906A1 (en) 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
WO2012108489A1 (ja) * 2011-02-10 2012-08-16 参天製薬株式会社 親水性薬物の薬物移行性を改善した水性組成物
DK2807178T3 (en) 2012-01-26 2017-09-04 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2R, 3S, 4R, 5R) -5- (6- (cyclopentylamino) -9H-purin-9-yl) -3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate and processes for their preparation
HK1214951A1 (zh) 2013-03-15 2016-08-12 Inotek Pharmaceuticals Corporation 眼用製劑
WO2017137528A1 (en) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus
KR102007640B1 (ko) 2017-11-29 2019-08-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
NZ545787A (en) * 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1663311A2 (en) * 2003-09-12 2006-06-07 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
NZ585697A (en) * 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
WO2008133129A1 (ja) * 2007-04-16 2008-11-06 Santen Pharmaceutical Co., Ltd. アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤

Also Published As

Publication number Publication date
BRPI0809953A2 (pt) 2014-09-23
JP2008266143A (ja) 2008-11-06
IL201418A0 (en) 2010-06-16
JP2010524933A (ja) 2010-07-22
CN101677544A (zh) 2010-03-24
KR20090128495A (ko) 2009-12-15
WO2008130520A1 (en) 2008-10-30
ZA200906989B (en) 2010-06-30
UA100376C2 (en) 2012-12-25
EP2134174A4 (en) 2011-05-25
EA015971B1 (ru) 2012-01-30
CA2684866A1 (en) 2008-10-30
US20100093770A1 (en) 2010-04-15
AU2008241496A1 (en) 2008-10-30
JP4923141B2 (ja) 2012-04-25
NZ580165A (en) 2012-07-27
EP2134174A1 (en) 2009-12-23
EA200901402A1 (ru) 2010-04-30
US20130109646A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
MX2009011076A (es) Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo.
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
TW200833675A (en) Nicotinamide derivatives
IL204621A (en) Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses
MX2009005616A (es) Derivados de pirido-pirazina utiles como compuestos herbicidas.
WO2008140099A1 (ja) テトラゾイルオキシム誘導体および植物病害防除剤
MX2013002558A (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
TW200800937A (en) Heterocyclic compound
TW200716619A (en) Heterocyclic compound
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
TW200637539A (en) CTGF inhibitors
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
MX2010006882A (es) Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
MX2010013275A (es) Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.
TW200716527A (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
MX2010001566A (es) Derivado de aminopirazolamida.
WO2008114812A1 (ja) Jak阻害剤
TW200745153A (en) Trehalose compound and pharmaceutical comprising the compound
RS51557B (en) 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ALFA 7 NICOTINE ACETYLHOLINE RECEPTORS
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
WO2008110690A3 (fr) Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens
MX2011009746A (es) Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-abril-metil]-hetero benzamida, su prepracion y su uso en terapeutica.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SANTEN PHARMACEUTICAL CO., LTD.

FA Abandonment or withdrawal